LytPhage and its collaborators at Temple University are developing novel antibiotic products that harness modified bacterial viruses (phage). They are an attractive alternative to synthetic and fermentation derived antimicrobials because phage can infect and kill only bacterial cells (and not mammalian cells). The technology can be applied to a long list urgent clinical problem like resistant staph, pseudomonas, C. difficile, and others.